ArticleCardiovascular toxicology2026
Potential Cardiovascular Risks of Phenethylamine Analogues in Food Supplements: Evidence from Vasocontraction of Rat Artery Segments.
Article in Cardiovascular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phenethylamine (PEA) and alkylamine (AA) analogues are frequently present in pre-workout food supplements and share structural similarity with amphetamine and the endogenous catecholamines (nor)adrenaline and dopamine, suggesting potential sympathomimetic activity. The present study investigated the vasoactive properties of PEA and AA analogues in isolated Wistar Kyoto rat mesenteric arteries, renal arteries and aorta. Our findings provide evidence that several analogues induced concentration-dependent contraction of isolated blood vessels, with potency (EC50) values ranging from 0.906 µM to 550 µM. p-Synephrine and p-octopamine were the only two substances that induced contraction of the mesenteric artery segments, whereas 6 out of 12 PEA analogues, including p-synephrine, p-octopamine, halostachine, β-methylphenethylamine, phenethylamine and dimethylphenethylamine, induced contraction of aorta and renal artery segments. These effects were largely attenuated by the α1-adrenergic receptor (ADR) antagonist prazosin, implicating ADRα1 involvement, while partial modulation by the trace amine associated receptor 1. The demonstrated vasocontractility of these compounds highlights the potential influence on the vascular tone and blood pressure regulation and the deleterious consequences for cardiovascular health in humans. These risks may be particularly pronounced in exercising individuals that have an already activated sympathetic nervous system or those with underlying cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.